TCRX logo

TSCAN THERAPEUTICS INC

TCRXNASDAQ
🏆 #4743 by market capEarnings Nov 11US Equity
$0.20▲ $0.01 (+3.58%)
Pre-market · at close
🔔
Track TCRX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 3.6%
7d▼ 9.4%
14d▼ 16.0%
30d▼ 37.6%
ytd▼ 79.9%
1y▼ 89.6%
🏦Market Cap
$14M
Small Cap
📈Revenue Growth (YoY)
2.1%
Slowing
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
1.8x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.18 – $0.20
52-Week Range
$0.18 – $2.43
Volume (shares)
5,571
Avg Volume (shares)
—
Shares Outstanding
67.8M
Next Earnings
2026-11-11

Fundamentals Snapshot

Annual Revenue
$10M
Last Q Revenue
$1M
P/E Ratio
—
P/S Ratio
1.8x
EPS (TTM)
$-0.91
Dividend Yield
—
Dilution (1yr)
+7.5%
TCRX logo

TSCAN THERAPEUTICS INC

TCRX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$10M▲ +266.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
72.2%▼ −27.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$136M▲ +0.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$140M▲ +21.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
129.9M▲ +7.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$58M▼ −$23M YoY
StockOtter · stockotter.space

About TSCAN THERAPEUTICS INC

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
11 analysts
Strong Buy2
Buy5
Hold4
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.